TORII PHARMACEUTICAL CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,020 JPY | +1.13% |
|
+6.35% | +13.08% |
| Feb. 13 | LIM Advisors Partially Withdraws Shareholder Proposal | CI |
| Feb. 09 | Torii Pharmaceuticals Opposes Shareholder Proposal | CI |
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The firm trades with high earnings multiples: 22.87 times its 2024 earnings per share.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +13.08% | 703M | - | ||
| +33.25% | 704B | C+ | ||
| +28.59% | 577B | B | ||
| -3.55% | 348B | C+ | ||
| +18.16% | 327B | B- | ||
| +4.36% | 288B | C+ | ||
| +14.81% | 234B | B+ | ||
| +4.93% | 198B | B- | ||
| -9.78% | 194B | A+ | ||
| -3.69% | 147B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4551 Stock
- Ratings Torii Pharmaceutical Co., Ltd.
